

GUFIC BIOSCIENCES LIMITED

Regd office : 37, First Floor, Kamala Bhavan II, S Nityanand Road, Andheri (East), Mumbai-400 069

AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED / YEAR ENDED 31.03.2016

Rs. In Lacs

Particulars	Quarter Ended 31.03.2016 Audited	Quarter Ended 31.03.2015 Audited	Quarter Ended 31.12.2015 Unaudited	For the Year Ended 31.03.2016 Audited	For the Year Ended 31.03.2015 Audited
INCOME:					
Net Sales / Income from Operations (Net of Excise Duty)	5709.26	3547.55	5605.97	20205.16	15142.61
Other Operating Income	1.94	6.90	5.42	26.61	32.53
Total Income from Operations (Net)	5711.20	3554.45	5611.39	20231.77	15175.14
EXPENSES:					
Cost of Materials Consumed	1856.16	1133.87	1969.38	7626.31	6579.76
Purchase of Stock-in-Trade	1870.76	472.44	1066.81	4280.95	1670.77
Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(695.94)	149.49	(112.58)	(1709.85)	(130.68)
Employee Benefits Expenses	770.36	647.57	835.21	3197.53	1933.33
Depreciation and Amortisation Expenses	94.80	77.29	96.96	378.68	385.21
Other Expenses	1290.90	867.28	1301.62	4856.12	3675.26
Total Expenses	5187.04	3347.94	5157.40	18629.74	14113.66
Profit from Operations before Other Income, finance costs and Exceptional Items	524.16	206.52	453.99	1602.03	1061.48
Other Income	4.62	21.28	14.28	54.24	37.18
Profit from ordinary activities before finance costs and exceptional items	528.78	227.80	468.27	1656.27	1098.66
Finance Costs	162.55	127.87	136.76	536.84	446.08
Profit from ordinary activities after finance costs but before exceptional items	366.23	99.93	331.50	1119.43	652.59
Exceptional Items	0.00	0.00	0.00	0.00	0.00
Profit from Ordinary Activities Before Tax	366.23	99.93	331.50	1119.43	652.59
Current Tax	142.10	18.50	100.00	429.30	278.61
Deferred Tax	2.62	(32.14)	(10.62)	(42.63)	(48.84)
Short/(Excess) Tax Provisions of Earlier Years	(0.01)	3.34	0.35	0.34	7.08
Net Profit from Ordinary Activities After Tax	221.52	110.23	241.77	732.42	415.74
Extraordinary Items (Net of Tax Expenses)	0.00	0.00	0.00	0.00	0.00
Net Profit for the Period	221.52	110.23	241.77	732.42	415.74
Paid up Equity Share Capital (Face Value of Rs 1 /- Each)	773.50	773.50	773.50	773.50	773.50
Reserves Excluding Revaluation Reserves	2622.37	1936.49	2447.39	2622.37	1936.49
E.P.S	0.29	0.14	0.31	0.95	0.54
Public Shareholding					
-- Number of Shares of Rs 1 /- Each	23222355	23222355	23222355	23222355	23222355
-- Percentage of shareholding	30.02%	30.02%	30.02%	30.02%	30.02%
Promoters and Promoter group Shareholding					
a) Pledged / Encumbered					
-- Number of Shares of Rs 1 /- Each	0	0	0	0	0
-- Percentage of Shares the total Shareholding of Promoter and Promoter group	0.00%	0.00%	0.00%	0.00%	0.00%
-- Percentage of Shareholding on total Capital of the company	0.00%	0.00%	0.00%	0.00%	0.00%
b) Non - Encumbered					
-- Number of Shares of Rs 1 /- Each	54127645	54127645	54127645	54127645	54127645
-- Percentage of Shares the total Shareholding of Promoter and Promoter group	100.00%	100.00%	100.00%	100.00%	100.00%
-- Percentage of Shareholding on total Capital of the company	69.98%	69.98%	69.98%	69.98%	69.98%

GUFIC BIOSCIENCES LIMITED

Regd office : 37, First Floor, Kamala Bhavan II, S Nityanand Road, Andheri (East), Mumbai-400 069


AUDITED SEGMENT WISE RESULTS FOR THE QUARTER / ENDED 31.03.2016					Rs. In Lacs
Particulars	Quarter Ended 31.03.2016 Audited	Quarter Ended 31.03.2015 Audited	Quarter Ended 31.12.2015 Unaudited	For the Year Ended 31.03.2016 Audited	For the Year Ended 31.03.2015 Audited
SEGMENT REVENUE					
Sales & Service					
Pharma	5655.29	3213.91	5424.01	19769.64	13922.95
Consumer	53.97	333.65	181.96	435.52	1219.66
Total	5709.26	3547.56	5605.97	20205.16	15142.61
Unallocabel Income	6.56	28.18	19.70	80.85	69.71
Total Segment Revenue	5715.82	3575.74	5625.67	20286.01	15212.32
SEGMENT RESULTS					
Pharma	1342.48	612.79	1096.44	4110.06	2701.05
Consumer	0.02	43.41	19.71	42.18	136.97
TOTAL	1342.49	656.20	1116.15	4152.23	2838.02
Less: Unallocated over heads	718.91	351.11	550.92	2117.28	1354.15
Finance Charges	162.55	127.87	136.76	536.84	446.08
Depreciation	94.80	77.29	96.96	378.68	385.21
Tax provision	144.71	(10.30)	89.73	387.01	236.85
Net Profit after Tax	221.52	110.23	241.77	732.42	415.74

AUDITED STATEMENT OF ASSETS AND LIABILITIES		
Particulars	AS AT 31.03.2016 Audited	AS AT 31.03.2015 Audited
EQUITY AND LIABILITIES		
Shareholder's Funds		
a) Share Capital	773.50	773.50
b) Reserves and Surplus	2,622.37	1,936.50
Sub-total - Shareholder's Funds	3395.87	2710.00
Non-current liabilities		
a) Long-term borrowings	772.02	1,150.34
b) Deferred tax liabilities (Net)	112.11	154.73
c) Other long-term liabilities	438.87	212.27
d) Long-term provisions	139.05	140.50
Sub-total - Non-current liabilities	1462.05	1657.84
Current liabilities		
a) Short-term borrowings	3,228.20	1,790.42
b) Trade payables	5,262.24	4,953.33
c) Other current liabilities	1,404.35	1,301.23
d) Short-term provisions	467.20	315.97
Sub-total - Current liabilities	10361.99	8360.95
TOTAL - EQUITY AND LIABILITIES	15219.91	12728.79
ASSETS		
Non-current assets		
a) Fixed assets	2,214.67	2,510.71
b) Non-current investments	0.93	0.93
c) Long-term loans and advances	729.93	800.78
d) Other non-current assets	309.49	268.48
Sub-total - Non-Current assets	3255.02	3580.90
Current assets		
a) Current investments		
b) Inventories	5,026.31	3,680.14
c) Trade receivables	5,622.80	3,338.40
d) Cash and cash equivalents	615.89	620.63
e) Short-term loans and advances	699.89	1,508.71
f) Other current assets		
Sub-total - Current assets	11964.89	9147.88
TOTAL - ASSETS	15219.91	12728.78

Notes forming part of the audited financial results for the quarter ended March 31, 2016

1. The above financial results have been reviewed by the Audit Committee of the Board and approved by the Board of Directors in their meetings held on May 30, 2016.
2. For the preparation of these financial results, the company has followed the same accounting policies and generally accepted practices adopted for the preparation of audited financial statements for the year ended March 31, 2016.
3. The figures of the last quarter of financial year 2015-16 are the balancing figures between audited figures in respect of the full financial year upto March 31, 2016 and the unaudited published year – to – date figures upto December 31, 2015 which were subject to limited review.
4. Disclosure about investor complaints: Complaints at the beginning of the period Nil, Received during the period Nil; Disposed off during the period: Nil, Unresolved as on March 31, 2016: Nil.
5. Corresponding previous period figures have been regrouped / rearranged wherever necessary to make them comparable with current period figures.

By Order of the Board
Gufic Biosciences Limited


Pranav J. Choksi
Chief Executive Officer & Executive Director
Mumbai dated May 30, 2016